An Gang
An Gang — Chief Physician — Lymphoma Center — Chinese Academy of Medical Sciences Hematology Hospital
Specialties
Diagnosis and treatment of plasma cell diseases (multiple myeloma, amyloidosis, rare plasma cell diseases, etc.) and lymphomas (diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma, Hodgkin lymphoma, peripheral T-cell lymphoma, etc.)
Education
Graduated in 2003 from Shandong Medical University with a major in Clinical Medicine. From 2006 to 2011, pursued a master's and doctoral degree at the Graduate School of Peking Union Medical College, with a primary research focus on the molecular genetics of multiple myeloma. From November 2013 to July 2016, conducted postdoctoral research at Harvard University's Dana-Farber Cancer Institute, with a main research focus on the immune microenvironment and targeted therapy of multiple myeloma.
Professional Experience
Currently serving at the Lymphoma Diagnosis and Treatment Center of the Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) as Chief Physician, Assistant Director of the Lymphoma Center, Leader of the Multiple Myeloma Group, Ph.D., Associate Professor, Master’s Supervisor, and Level II PI of the National Key Laboratory of Experimental Hematology. Recipient of the 2020 China Young Scientist Award in Oncology, a first-level talent in the Tianjin 131 Innovative Talent Training Program, and a young medical talent selected in the Tianjin Health and Family Planning High-Level Talent Selection and Training Program. From 2003 to 2006, worked as a resident physician at the Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology). During doctoral studies (2010), went to the Karolinska Cancer Center in Sweden for short-term study, and after returning to China, helped establish a fluorescent probe production and QM-FISH technology platform to conduct research on clonal evolution at the single-cell level. In 2012, went to the International Myeloma Foundation in the United States for short-term training. Principal investigator of two National Natural Science Foundation projects and five other funded projects, and participated as the main executor in an international cooperation project of the National Natural Science Foundation. Developed a clonal evolution detection kit and obtained a patent.
Professional Roles
Deputy Director of the 2nd Youth Committee of the Hematologic Oncology Branch of the China Anti-Cancer Association; Member of the 11th Youth Committee of the Hematology Branch of the Chinese Medical Association; Youth Councilor of the China Anti-Cancer Association; Member of the Hematologic Disease Translational Committee of the China Anti-Cancer Association; Member of the Targeted Therapy Group of the Experimental Hematology Professional Committee of the Chinese Society of Pathophysiology; Member and Secretary of the China Multiple Myeloma Research Alliance; Secretary of the Hematologic Oncology Committee of the China Anti-Cancer Association; Deputy Leader of the China Rare Plasma Cell Disease Collaboration Group; Tianjin Anti-Cancer Association Elderly Tumor Professional Committee; Member of the Tianjin Genetic Counseling Committee; Corresponding Editor of the Chinese Journal of Hematology